At the news
? BULLISHIMPACT 7/10 8-K filed Feb 26, 2026 at 07:04 ET
Akebia Therapeutics reported strong financial results for Q4 and full-year 2025, with total revenues of $57.6 million (Q4) and $236.2 million (full-year), representing significant year-over-year growth. The increase was driven by Vafseo sales following its 2025 U.S. launch and higher Auryxia volumes. The company reported a reduced net loss and expects Vafseo revenue growth in 2026 due to expanded access and improved adherence, though Auryxia revenues are expected to decline due to generic competition.
- Q4 2025 total revenues: $57.6 million (up from $46.5 million in Q4 2024)
- Full-year 2025 total revenues: $236.2 million (up from $160.2 million in 2024)
- Vafseo net product revenues: $6.2 million in Q4 2025 and $45.8 million for full-year 2025
- Auryxia net product revenues: $48.1 million in Q4 2025 (up from $44.4 million in Q4 2024)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access